Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
World J. Clin. Cases ; 14(8): 2893-2901, 20200726.
Article in English | ELSEVIER | ID: covidwho-692305

ABSTRACT

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 has spread rapidly around the world and is a significant threat to global health. Patients in the Neonatal Surgery Department have rapidly progressing diseases and immature immunity, which makes them vulnerable to pulmonary infection and a relatively higher mortality. This means that these patients require multidisciplinary treatment including early diagnosis, timely transport, emergency surgery and intensive critical care. The COVID-19 pandemic poses a threat to carrying out these treatments. To provide support for the health protection requirements of the medical services in the Neonatal Surgery Department, we developed recommendations focusing on patient transport, surgery selection and protection requirements with the aim of improving treatment strategies for patients and preventing infection in medical staff during the current COVID-19 pandemic.

4.
Medicine (Baltimore) ; 99(24): e20612, 2020 Jun 12.
Article in English | MEDLINE | ID: covidwho-593914

ABSTRACT

BACKGROUND: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome (SARS)-COV2 and represents the causative agent of a potentially fatal disease. Jinhua Qinggan granules has definite effect in treating COVID-19 patients, but it has not been systematically evaluated for efficacy and safety. METHODS: Retrieved the database, including the China National Knowledge Infrastructure (CNKI), Chinese Biomedical literature Database (CBM), Chinese Scientific and Journal Database (VIP), Wan Fang database, PubMed, and EMBASE. Evaluate methodological quality and judge risk of bias through the Cochrane manual. RevMan 5.3 and STATA 16.0 software were used to perform the meta-analysis. RESULTS: This study will provide high-quality evidence of Jinhua Qinggan granules for COVID-19. CONCLUSION: The conclusion of this study will provide evidence to determine whether Jinhua Qinggan granules is an effective treatment for COVID-19. PROSPERO REGISTRATION NUMBER: CRD42020182373.


Subject(s)
Betacoronavirus , Coronavirus Infections/drug therapy , Drugs, Chinese Herbal/therapeutic use , Pneumonia, Viral/drug therapy , Drugs, Chinese Herbal/adverse effects , Humans , Meta-Analysis as Topic , Pandemics , Randomized Controlled Trials as Topic , Systematic Reviews as Topic
5.
Medicine (Baltimore) ; 99(22): e20489, 2020 May 29.
Article in English | MEDLINE | ID: covidwho-480668

ABSTRACT

BACKGROUND: The corona virus disease 2019 (COVID-19) has caused a global pandemic, there are no specific drugs and vaccines for epidemic control at present. More and more clinical practice shows that traditional Chinese medicine has played an important role in the outbreak. Among them, Qingfei Paidu decoction (QPD) combined with antiviral drugs can enhance the therapeutic efficacy for COVID-19. However, there is still a lack of comprehensive and systematic evidence, which urgently requires us to verify its therapeutic efficacy. Hence, we provide a protocol for systematic review and meta-analysis. METHODS: We will search the studies in MEDLINE/PubMed, China National Knowledge Infrastructure, Wanfang database, VIP database, the Cochrane Library, Chinese Biomedical Database and Chinese Science Citation Database. Searches are limited to clinical studies published in Chinese and English. Next, the quality of each study is assessed according to the criteria of the Cochrane Handbook for Systematic Reviews of Interventions. Then, the outcome data are recorded and pooled by Review Manager 5.3 and STATA 16.0 software. RESULTS: The systematic review and meta-analysis aims to review and pool current clinical outcomes of QPD combined with antiviral drugs for the treatment of COVID-19. CONCLUSION: This study will provide a high-quality evidence of QPD for the treatment on COVID-19 patients. PROSPERO REGISTRATION NUMBER: CRD42020182409.


Subject(s)
Antiviral Agents/therapeutic use , Coronavirus Infections/drug therapy , Drugs, Chinese Herbal/therapeutic use , Meta-Analysis as Topic , Pneumonia, Viral/drug therapy , Research Design , Systematic Reviews as Topic , Drug Combinations , Humans , Pandemics , Treatment Outcome
6.
Chin. Trad. Herbal Drugs ; 7(51): 1776-1784, 20200412.
Article in Chinese | ELSEVIER | ID: covidwho-378896

ABSTRACT

Objective: To research the mechanism of Xinguanzhongqizhenliao formula (XGZQZLF) for COVID-19 treatment by network pharmacology. Methods: “Drug-active ingredient-target-disease” network was constructed by Cytoscape based on TCMSP and GeneCards databases. Mechanism of XGZQZLF in treatment of COVID-19 was implemented by GO and KEGG analysis. Results: A total of 80 active ingredients of XGZQZLF were screened out. They could regulate 208 targets of COVID-19, including AKT1, IL-6, MAPK3, VEGFA, CASP3 and so on, which exerted therapeutic effect on COVID-19 through regulating multiple signaling pathways such as TNF signaling pathway, IL-17 signaling pathway, Th17 cell differentiation, HIF-1 signaling pathway and so on. Conclusion: XGZQZLF plays an important role in the treatment of COVID-19 through multi-component, multi-target and multi-pathway, which can provide reference for the synergistic theory of TCM compound prescription.

9.
Yi Chuan ; 42(2): 212-221, 2020 Feb 20.
Article in English | MEDLINE | ID: covidwho-3031

ABSTRACT

An ongoing outbreak of a novel coronavirus infection in Wuhan, China since December 2019 has led to 31,516 infected persons and 638 deaths across 25 countries (till 16:00 on February 7, 2020). The virus causing this pneumonia was then named as the 2019 novel coronavirus (2019-nCoV) by the World Health Organization. To promote the data sharing and make all relevant information of 2019-nCoV publicly available, we construct the 2019 Novel Coronavirus Resource (2019nCoVR, https://bigd.big.ac.cn/ncov). 2019nCoVR features comprehensive integration of genomic and proteomic sequences as well as their metadata information from the Global Initiative on Sharing All Influenza Data, National Center for Biotechnology Information, China National GeneBank, National Microbiology Data Center and China National Center for Bioinformation (CNCB)/National Genomics Data Center (NGDC). It also incorporates a wide range of relevant information including scientific literatures, news, and popular articles for science dissemination, and provides visualization functionalities for genome variation analysis results based on all collected 2019-nCoV strains. Moreover, by linking seamlessly with related databases in CNCB/NGDC, 2019nCoVR offers virus data submission and sharing services for raw sequence reads and assembled sequences. In this report, we provide comprehensive descriptions on data deposition, management, release and utility in 2019nCoVR, laying important foundations in aid of studies on virus classification and origin, genome variation and evolution, fast detection, drug development and pneumonia precision prevention and therapy.


Subject(s)
Betacoronavirus , Coronavirus Infections/epidemiology , Databases, Genetic , Information Dissemination , Pneumonia, Viral/epidemiology , Pneumonia, Viral/virology , China , Coronavirus , Coronavirus Infections/virology , Genomics , Humans , Pandemics , Proteomics
SELECTION OF CITATIONS
SEARCH DETAIL